231 related articles for article (PubMed ID: 24209634)
41. Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.
Xie C; Han Y; Fu L; Li Q; Qiu X; Wang E
Tumour Biol; 2014 Aug; 35(8):7957-64. PubMed ID: 24833094
[TBL] [Abstract][Full Text] [Related]
42. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
43. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
44. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
[TBL] [Abstract][Full Text] [Related]
46. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a.
Huang L; Wang HY; Li JD; Wang JH; Zhou Y; Luo RZ; Yun JP; Zhang Y; Jia WH; Zheng M
Cell Death Dis; 2013 Aug; 4(8):e745. PubMed ID: 23907459
[TBL] [Abstract][Full Text] [Related]
47. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
48. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
49. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
50. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
51. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
52. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.
Matsushita Y; Yokoyama Y; Yoshida H; Osawa Y; Mizunuma M; Shigeto T; Futagami M; Imaizumi T; Mizunuma H
J Ovarian Res; 2014 Nov; 7():107. PubMed ID: 25424877
[TBL] [Abstract][Full Text] [Related]
53. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
54. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
[TBL] [Abstract][Full Text] [Related]
55. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
[TBL] [Abstract][Full Text] [Related]
56. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
57. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
58. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
59. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
60. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
Liu L; Guo J; Yu L; Cai J; Gui T; Tang H; Song L; Wang J; Han F; Yang C; Chen C; Marks A; Wang Z
Tumour Biol; 2014 Dec; 35(12):12619-26. PubMed ID: 25260883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
